Transplantation of RPE in Age-related Macular Degeneration: Observations in Disciform Lesions and Dry RPE Atrophy
Overview
Authors
Affiliations
Unlabelled: A study was carried out to investigate whether human RPE allografts are tolerated or rejected in the subretinal space and to determine the feasibility of RPE transplantation in subjects with age-related macular degeneration (AMD).
Methods: Patches of human fetal RPE (13-20 weeks of gestational age) were transplanted into the subretinal space of five patients after surgical removal of subfoveal fibrovascular membranes, and to four subjects with dry geographic atrophy. Suspensions of RPE cells were transplanted to four other patients with nonexudative AMD. Results were evaluated with clinical ophthalmological examination, SLO microperimetry and fluorescein angiography over 8-20 months.
Results: In disciform lesions, RPE transplants developed macular edema and fluorescein leakage concomitant with gradual reduction of visual acuity, implying host-graft rejection, over 1-6 months. In geographic atrophy, three of four transplants showed little change in shape and size after 12 months (one transplant was slowly rejected). In non-exudative AMD, RPE suspension transplants showed no evidence of rejection and were associated with the disappearance of drusen; visual acuity remained stable and SLO microperimetry confirmed retinal function over the transplanted area.
Conclusion: Human RPE allografts are not invariably rejected in the subretinal space without immunosuppression. The rejection rate is lower in nonexudative than in neovascular AMD. An intact blood-retinal barrier is likely to protect against rejection. It is technically feasible to transplant human RPE into the submacular space without adversely affecting visual function in nonexudative AMD over relatively long periods of time.
Subretinal microglia support donor photoreceptor survival in rd1 mice.
Ren Q, Lu F, Hao R, Chen Y, Liang C Stem Cell Res Ther. 2024; 15(1):436.
PMID: 39563450 PMC: 11575076. DOI: 10.1186/s13287-024-04052-0.
Atrophic Macular Degeneration and Stem Cell Therapy: A Clinical Review.
Babighian S, Zanella M, Gattazzo I, Galan A, Gagliano C, DEsposito F Adv Exp Med Biol. 2024; 1474():105-118.
PMID: 39259423 DOI: 10.1007/5584_2024_819.
Advances in the study of tissue-engineered retinal pigment epithelial cell sheets.
Zhou W, Chai Y, Lu S, Yang Q, Tang L, Zhou D Regen Ther. 2024; 27:419-433.
PMID: 38694444 PMC: 11062139. DOI: 10.1016/j.reth.2024.04.008.
Retinal Pigment Epithelium Transplantation: Past, Present, and Future.
Khan A, Utheim T, Eidet J J Ophthalmic Vis Res. 2023; 17(4):574-580.
PMID: 36620704 PMC: 9806312. DOI: 10.18502/jovr.v17i4.12325.
Ocular stem cells: a narrative review of current clinical trials.
Sotiropulos K, Kourkoutas D, Almaliotis D, Ploumidou K, Karampatakis V Int J Ophthalmol. 2022; 15(9):1529-1537.
PMID: 36124200 PMC: 9453397. DOI: 10.18240/ijo.2022.09.17.